Claims
- 1. A pathogen reduction solution for suspending platelets undergoing a pathogen reduction procedure comprising;
an endogenous photosensitizer; and a glycolytic inhibitor.
- 2. A pathogen reduction solution of claim 1 further comprising a solvent.
- 3. The pathogen reduction solution of claim 1 wherein the endogenous photosensitizer further comprises 7,8-dimethyl-10-ribityl isoalloxazine.
- 4. The pathogen reduction solution of claim 1 wherein the glycolytic inhibitor is selected from the group consisting of 2-deoxy-D-glucose, xylose, arabinose and lyxose.
- 5. The pathogen reduction solution of claim 1 wherein the glycolytic inhibitor is added to the solution at a concentration of between 1 mM to 10 mM.
- 6. The pathogen reduction solution of claim 1 wherein the glycolytic inhibitor is 2-deoxy-D-glucose at a concentration of 10 mM.
- 7. The pathogen reduction solution of claim 2 wherein the solvent is selected from the group consisting of PSS 1, PSS 2, PSS 3, PSS 4, PSS 5, PSS 6, PSS 7, PSS 8 and PSS 9.
- 8. The pathogen reduction solution of claim 2 wherein the solvent is selected from the group consisting of saline and water.
- 9. The pathogen reduction solution of claim 1 further comprising a quencher selected from the group consisting of adenine, histidine, cysteine, tyrosine, tryptophan, ascorbate, N-acetyl-L-cysteine, propyl gallate, glutathione, mercaptopropionylglycine, dithiothreotol, nicotinamide, BHT, BHA, lysine, serine, methionine, glucose, mannitol, trolox, glycerol, and mixtures thereof.
- 10. A storage solution for suspending platelets which have undergone a pathogen reduction procedure comprising;
an endogenous photosensitizer; and a glycolytic inhibitor.
- 11. A storage solution of claim 10 further comprising a solvent.
- 12. The storage solution of claim 10 wherein the endogenous photosensitizer further comprises 7, 8-dimethyl-10-ribityl isoalloxazine.
- 13. The storage solution of claim 10 wherein the glycolytic inhibitor is selected from the group consisting of 2-deoxy-D-glucose, xylose, arabinose and lyxose.
- 14. The pathogen reduction solution of claim 10 wherein the glycolytic inhibitor is added to the solution at a concentration of between 1 mM to 10 mM.
- 15. The pathogen reduction solution of claim 10 wherein the glycolytic inhibitor is 2-deoxy-D-glucose at a concentration of 10 mM.
- 16. The storage solution of claim 11 wherein the solvent is selected from the group consisting of PSS 1, PSS 2, PSS 3, PSS 4, PSS 5, PSS 6, PSS 7, PSS 8 and PSS 9.
- 17. The storage solution of claim 11 wherein the solvent is selected from the group consisting of saline and water.
- 18. The pathogen reduction solution of claim 10 further comprising a quencher selected from the group consisting of adenine, histidine, cysteine, tyrosine, tryptophan, ascorbate, N-acetyl-L-cysteine, propyl gallate, glutathione, mercaptopropionylglycine, dithiothreotol, nicotinamide, BHT, BHA, lysine, serine, methionine, glucose, mannitol, trolox, glycerol, and mixtures thereof.
- 19. A method of substantially reducing pathogens in a fluid containing platelets comprising:
adding an effective, non-toxic amount of an endogenous photosensitizer to the fluid; adding an effective amount of a glycolytic inhibitor; and exposing the fluid to photoradiation sufficient to activate the photosensitizer and substantially reduce the pathogens.
- 20. The method of claim 19 wherein the endogenous photosensitizer further comprises 7,8-dimethyl-10-ribityl isoalloxazine.
- 21. The method of claim 19 wherein the glycolytic inhibitor is selected from the group consisting of 2-deoxy-D-glucose, xylose, arabinose and lyxose.
- 22. The method of claim 19 wherein the glycolytic inhibitor is added to the solution at a concentration of between 1 mM to 10 mM.
- 23. The method of claim 19 wherein the glycolytic inhibitor is 2-deoxy-D-glucose at a concentration of 10 mM.
- 24. A method of maintaining the viability of platelets during a pathogen reduction procedure comprising:
adding an effective, non-toxic amount of an endogenous photosensitizer to the fluid; adding an effective amount of a glycolytic inhibitor; and exposing the fluid to photoradiation sufficient to activate the photosensitizer and substantially reduce the pathogens.
- 25. A method of maintaining the viability of platelets after a pathogen reduction procedure comprising:
adding an effective, non-toxic amount of an endogenous photosensitizer to the fluid; exposing the fluid to photoradiation sufficient to activate the photosensitizer and substantially reduce the pathogens and adding an effective amount of a glycolytic inhibitor.
CROSS REFERENCE To RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional patent application No. 60/353,319 filed Feb. 1, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60353319 |
Feb 2002 |
US |